Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price traded down 1.6% during trading on Wednesday . The stock traded as low as $50.58 and last traded at $51.20, with a volume of 170,908 shares. The stock had previously closed at $52.01.

Several equities analysts have commented on the stock. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Jefferies Group set a $60.00 target price on shares of Five Prime Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Leerink Swann reissued a “buy” rating and set a $45.00 target price on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $52.33.

The company has a 50 day moving average price of $47.55 and a 200-day moving average price of $43.93. The company has a market cap of $1.42 billion, a P/E ratio of 5.94 and a beta of 4.51.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/five-prime-therapeutics-inc-fprx-shares-down-1-6.html

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a net margin of 63.88% and a return on equity of 69.59%. The company earned $9.23 million during the quarter, compared to the consensus estimate of $6.38 million. During the same period in the prior year, the firm earned ($0.45) earnings per share. Five Prime Therapeutics’s revenue was up 46.1% on a year-over-year basis. Equities analysts expect that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current fiscal year.

In other Five Prime Therapeutics news, Director William R. Ringo sold 500 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $50.77, for a total value of $25,385.00. Following the sale, the director now owns 500 shares in the company, valued at $25,385. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peder Jensen sold 12,195 shares of the company’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total transaction of $603,652.50. Following the completion of the sale, the director now owns 12,195 shares in the company, valued at approximately $603,652.50. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Five Prime Therapeutics by 24.1% in the second quarter. FMR LLC now owns 2,817,208 shares of the company’s stock worth $116,492,000 after buying an additional 547,808 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in Five Prime Therapeutics by 11.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,600,000 shares of the company’s stock worth $105,638,000 after buying an additional 275,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in Five Prime Therapeutics by 43.5% in the second quarter. Vanguard Group Inc. now owns 1,472,276 shares of the company’s stock worth $60,877,000 after buying an additional 446,311 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Five Prime Therapeutics by 112.1% in the second quarter. Acadian Asset Management LLC now owns 1,094,368 shares of the company’s stock worth $45,250,000 after buying an additional 578,411 shares during the last quarter. Finally, State Street Corp boosted its stake in Five Prime Therapeutics by 28.5% in the second quarter. State Street Corp now owns 1,057,836 shares of the company’s stock worth $43,741,000 after buying an additional 234,648 shares during the last quarter. Institutional investors and hedge funds own 86.49% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.